NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

The Spurs phenom suffered a season-ending injury. A physician explains what deep vein thrombosis is, its causes and treatment ...

This $330 smartwatch can outlast its competitors in battery life and fitness features, but may fall short on software updates ...

Investment in robotics may be substantial, but long-term benefits of automation include lower labour costs and more ...

In the Amazon biblical series 'House of David," the hero is a stone slinger with golden pipes and Goliath would put the fright into puny Thanos.

Sea Limited (NYSE: SE) has been one of the most interesting tech companies to watch for the last few years. At one point, it ...

The Dell UtraSharp 32 4K Thunderbolt Hub Monitor is a solid value. It offers a crisp, vivid IPS Black 4K display for under $1 ...

Amid a torrent of troubling headlines, FT Edit brings you eight things to look forward to over the coming months ...

Nunez has an unusually short stride for a hard thrower, falls to the first base side while spinning off his landing heel and ...

Would Quantum breakthroughs and AI Supercomputers finally make the elusive super-machine affordable, accessible and lean ...

Ragin’, aren’t they? Not just the Dundee United coaching staff and players. But a whole host of neutrals leaping up and down ...

Many stocks in the healthcare sector have trailed the wider markets, but are there pockets of opportunity? TD Asset Management's Ram Sampath discusses.